DCPH Stock Forecast - 2022, 2023, 2025 |GlobalFinanceTrends

DCPH Stock Forecast: DCPH News – 2022, 2023, 2024, 2025

31
DCPH Stock Forecast: DCPH News – 2022, 2023, 2024, 2025

DCPH Stock Forecast

DCPH Stock Forecast: 2022, 2023, 2024, 2025, 2030

Deciphera Pharmaceuticals news highlights that during the early trading session on Friday, Deciphera Stock price was down 71.6 percent at $10.24.

The shares of Deciphera Pharmaceuticals Inc, Deciphera Pharmaceuticals Stock, fell to a 52-week low after the company announced unsatisfactory findings from the INTRIGUE Phase 3 research of Qinlock in patients with gastrointestinal stromal tumor (GIST) who had recently been treated with Novartis AG’s (NYSE: NVS) Gleevec.

How Many Employees Does Deciphera Pharmaceuticals Have?

The company of Deciphera Pharmaceuticals Stock has 441 employees.

When Did Deciphera Go Public?

According to official DCPH News, on September 27, 2017, Deciphera Pharmaceuticals, Inc. (Deciphera Pharmaceuticals Stock), a clinical-stage biopharmaceutical firm focused on solving key mechanisms of tumor drug resistance, revealed the pricing of its initial public offering of 7,500,000 shares of common stock, Deciphera Pharmaceuticals Stock, at a public offering price (Deciphera Stock price) of $17.00 per share for aggregate gross proceeds of $127,500,000.

When Was Deciphera Founded?

When Was Deciphera Founded

Company of Deciphera Pharmaceuticals Stock was founded in 2003.

Why Is Deciphera Stock Price Increased 70%?

When a stock falls by 75% in a short period of time, traders have cause to worry. When such a change is detected during a trading day, it’s time to make a noise. Such tends to be the present situation for Deciphera Pharmaceuticals Stock (NASDAQ:DCPH) and DCPH stock investors, as per the Deciphera Pharmaceuticals news.

This tremendous daily movement in Deciphera Stock price is noteworthy for a number of reasons, as it seen on the Deciphera Pharmaceuticals news. Up until today, Deciphera Pharmaceuticals Stock has had some very good momentum over the previous month. This was a biopharmaceutical stock with a lot of interest.

It is significant that the firm is focused on improving the lives of people with cancer by improving the durability of reaction and addressing other important difficulties that afflict cancer medications. This is a corporation on a goal to change the world. And Deciphera is hopeful that their QINLOCK therapy for gastrointestinal (GI) tumors will be the cure the pharmaceutical industry has been looking for.

14 Days Historical Data of Deciphera Stock Price

Date Opening price Closing price Minimum price Maximum price
2021-11-05 Open: 9.15 Close: 8.81 Low: 8.81 High: 9.525
2021-11-04 Open: 36.465 Close: 36 Low: 35.97 High: 36.995
2021-11-03 Open: 35.44 Close: 37.13 Low: 35.44 High: 37.54
2021-11-02 Open: 33.94 Close: 35.1 Low: 33.94 High: 35.1
2021-11-01 Open: 33.1 Close: 34.31 Low: 33.1 High: 34.53
2021-10-29 Open: 34.49 Close: 33.39 Low: 33.39 High: 34.92
2021-10-28 Open: 33.79 Close: 34.46 Low: 33.79 High: 34.81
2021-10-27 Open: 33.99 Close: 33.87 Low: 33.67 High: 34.36
2021-10-26 Open: 33.66 Close: 33.89 Low: 33.66 High: 34.65
2021-10-25 Open: 34.62 Close: 34.01 Low: 33.9 High: 34.815
2021-10-22 Open: 33.21 Close: 34.6 Low: 33.2 High: 34.6
2021-10-21 Open: 34.87 Close: 34.04 Low: 33.84 High: 34.89
2021-10-20 Open: 33.52 Close: 34.21 Low: 33.485 High: 34.235
2021-10-19 Open: 33.83 Close: 33.97 Low: 33.83 High: 34.75

What Does Deciphera Pharmaceuticals Do?

Deciphera Pharmaceuticals, Inc. is a pharmaceutical firm that produces medications to improve the lives of people with cancer by targeting critical aspects of drug resistance that restrict the rate and duration of response to recent cancer treatments. Its principal therapeutic target is QINLOCK, which is being studied in the INTRIGUE Phase 3 research to treat second-line gastrointestinal stromal tumors (GIST).

The business is also working to develop immunokinase inhibitors, including vimseltinib (DCC-3014), that’s in a Stage 1b/2 medical study for the therapies of tenosynovial giant cell tumors, and Rebastinib, that is in a Stage 1b/2 medical study for the treatment of metastatic solid tumors, and also for use in combination with chemotherapy for the treatment of multiple solid tumors. Furthermore, DCC-3116 is being tested in preclinical studies to cure RAS/RAF mutant tumors. The business has operations in both the United States and Europe. Deciphera Pharmaceuticals, Inc., based in Waltham, Massachusetts, was formed in 2003.

DCPH News

DCPH News

The Deciphera Pharmaceuticals Stock (NASDAQ: DCPH) fell to a 52-week low after the company announced unsatisfactory findings from the INTRIGUE Phase 3 trial of Qinlock in people with gastrointestinal stromal tumor (GIST) who had recently been treated with Novartis AG’s (NYSE: NVS) Gleevec (imatinib).

On the Deciphera Pharmaceuticals news, it is highlighted that the main goal of increased progression-free survival (PFS) compared to the quality of care Pfizer Inc’s (NYSE: PFE) Sutent was not met. The entire findings of the INTRIGUE Phase 3 clinical trial will be published at a future medical symposium.

453 individuals were randomly assigned to receive either Qinlock 150 mg once daily or sunitinib 50 mg once day for four weeks, linked to two weeks without sunitinib.

The main outcome objective of progression-free survival (PFS) was not met in this trial.

Qinlock revealed a median PFS (mPFS) of 8.3 months in patients with a KIT exon 11 main mutation (n=327) comparing to 7.0 months in the sunitinib arm.

Even though not technically assessed because of the hierarchical testing sequence restrictions, Qinlock revealed a mPFS of 8.0 in the all patient intent-to-treat (AP) sample.

DCPH Stock Forecast

According to Deciphera price predictions, Deciphera Pharmaceuticals’ anticipated yearly profits growth rate of N/A is not expected to outperform the US Biotechnology industry’s average DCPH Stock Forecast earnings growth rate of 35.51 percent, nor is it expected to outperform the US market’s average DCPH Stock Forecast earnings growth rate of 16.15 percent. In 2021, Deciphera Pharmaceuticals’ profits will be -$274,309,000. As per the DCPH Stock Forecast for 2021, the stock price is expected to be $-285,386,485, with the lowest DCPH Stock Forecast at $-295,913,035 and the highest DCPH Stock Forecast at $-274,859,934.

DCPH Stock Forecast for the next days and 2021, 2022, 2023, 2024, 2025, 2026:

Date Price Min Price Max Price
2021-11-09 Price: 14.276 Min: 8.062 Max: 20.926
2021-11-10 Price: 14.735 Min: 8.996 Max: 20.864
2021-11-11 Price: 14.883 Min: 8.439 Max: 20.753
2021-11-12 Price: 7.939 Min: 1.792 Max: 13.976
2021-11-15 Price: 12.457 Min: 6.074 Max: 18.888
2021-11-16 Price: 13.050 Min: 7.060 Max: 19.164
2021-11-17 Price: 13.509 Min: 7.326 Max: 19.926
2021-11-18 Price: 13.657 Min: 7.469 Max: 19.640
2021-11-19 Price: 6.713 Min: 0.383 Max: 12.952

 

DCPH Stock Forecast data:

  • Current Deciphera Stock price is 8.810 USD.
  • The Deciphera Stock price can increase from 8.810 USD to 18.855 USD in one year, as per the Deciphera price predictions.
  • 52-week high Deciphera price prediction is 44.851 USD.
  • 52-week low Deciphera price prediction is 12.492 USD.
  • 45-Day Moving Average of Deciphera price predictions is 40.597 USD.
  • 90-Day Moving Average of Deciphera price predictions is 39.348 USD.
  • According to the Deciphera price prediction 2021, 2022, 2023, 2024, 2025, 2030 charts, the long-term profit potential is +114.02% in one year.

Below you can check the Deciphera price predictions for 2021, 2022, 2023, 2024, 2025, 2030.

DCPH Stock Forecast 2021

Date Opening price Closing price Minimum price Maximum price
December 2021 Open: 39.113 Close: 43.781 Min: 38.809 Max: 44.851
DCPH Stock Forecast 2022
January 2022 Open: 42.735 Close: 33.180 Min: 33.180 Max: 42.735
February 2022 Open: 33.412 Close: 26.387 Min: 26.387 Max: 33.412
March 2022 Open: 26.348 Close: 17.904 Min: 17.886 Max: 26.348
April 2022 Open: 17.814 Close: 20.581 Min: 17.814 Max: 21.317
May 2022 Open: 20.172 Close: 19.234 Min: 17.808 Max: 20.303
June 2022 Open: 19.241 Close: 19.861 Min: 19.241 Max: 20.787
July 2022 Open: 19.605 Close: 14.248 Min: 14.248 Max: 19.605
August 2022 Open: 13.809 Close: 12.987 Min: 12.492 Max: 13.972
September 2022 Open: 12.913 Close: 16.676 Min: 12.839 Max: 17.097
October 2022 Open: 16.452 Close: 17.481 Min: 13.622 Max: 17.481
November 2022 Open: 18.386 Close: 23.374 Min: 18.386 Max: 24.873
December 2022 Open: 23.161 Close: 28.282 Min: 22.973 Max: 29.136
DCPH Stock Forecast 2023
January 2023 Open: 27.413 Close: 17.679 Min: 17.446 Max: 27.413
February 2023 Open: 17.463 Close: 10.953 Min: 10.953 Max: 17.463
March 2023 Open: 10.466 Close: 1.918 Min: 1.918 Max: 10.466
April 2023 Open: 2.208 Close: 4.904 Min: 2.208 Max: 5.558
May 2023 Open: 4.551 Close: 3.228 Min: 1.962 Max: 4.694
June 2023 Open: 3.238 Close: 3.910 Min: 3.238 Max: 4.979
July 2023 Open: 3.624 Close: 0.0251 Min: 0.0251 Max: 3.804
August 2023 Open: 0.0188 Close: 0.000034 Min: 0.0000335 Max: 0.0188
September 2023 Open: 0.000025 Close: 0.880 Min: 0.000001063 Max: 1.185
October 2023 Open: 0.773 Close: 1.815 Min: 0.000437 Max: 1.815
November 2023 Open: 2.266 Close: 7.432 Min: 2.266 Max: 9.109
December 2023 Open: 7.200 Close: 12.696 Min: 7.200 Max: 13.327
DCPH Stock Forecast 2024
January 2024 Open: 12.025 Close: 1.729 Min: 1.717 Max: 12.025
February 2024 Open: 1.516 Close: 0.0070052 Min: 0.0070052 Max: 1.516
March 2024 Open: 0.00525 Close: 0.000017 Min: 0.0000167 Max: 0.00525
April 2024 Open: 0.000012 Close: 0.000001 Min: 0.000001 Max: 0.0000125
May 2024 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
June 2024 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
July 2024 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
August 2024 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
September 2024 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
October 2024 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
November 2024 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
December 2024 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
DCPH Stock Forecast 2025
January 2025 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
February 2025 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
March 2025 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
April 2025 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
May 2025 Open: 0.000001 Close: 0.000001 Min: 0.000001 Max: 0.000001
  • As per the 5 Wall Street experts offering 12 month DCPH Stock Forecast chart and Deciphera price predictions in the last 3 months, the average Deciphera price prediction is $67.00 with a high DCPH Stock forecast of $70.00 and a low DCPH Stock forecast of $60.00.